Earnings Call Summary | GETINGE AB(GNGBF.US) Q2 2024 Earnings Conference
Earnings Call Summary | GETINGE AB(GNGBF.US) Q2 2024 Earnings Conference
Gross profit increased by SEK837 million to SEK4,151 million, with adjusted gross margin improving across all business areas.The following is a summary of the Getinge AB (GNGBF) Q2 2024 Earnings Call Transcript:
以下爲Getinge Ab(GNGBF)2024財年第二季度業績會摘要：
Financial Performance:
金融業績：
Getinge reported a 15.7% increase in net sales and 14.4% growth in order intake in Q2 2024.
Adjusted EBITDA margin improved by 4.9 percentage points year-on-year.
Gross profit increased by SEK837 million to SEK4,151 million, with adjusted gross margin improving across all business areas.
Getinge報告2024年第二季度淨銷售額增長15.7%，訂單收入增長14.4%。
調整後的EBITDA邊際率同比提高4.9個百分點。
毛利潤增加了8369百萬瑞典克朗至41510百萬瑞典克朗，調整後各業務領域毛利率均有所提高。
Business Progress:
業務進展：
Launched Poladus 150, an advanced low-temperature sterilizer, and received 510(k) clearance and EU MDR approval for new products.
Presented an updated earnings per share target with an average growth of over 12% for 2024-2028 during the Capital Market Update.
Advanced the quality improvement for products like Cardiosave and Cardiohelp and made progress towards sustainable productivity improvements.
推出了先進的低溫滅菌器Poladus 150，並獲得了新產品的510(k)和歐盟MDR批准。
在資本市場更新中，提出了更新後的每股收益目標，2024-2028年的平均增長率超過12%。
推進Cardiosave和Cardiohelp等產品的質量改進，並取得可持續生產力改進方面的進展。
Opportunities:
機會：
The company continues to see good market opportunities in Asia Pacific, expecting strong demand for healthcare.
Recent acquisitions are expected to contribute to 3-5 percentage points of growth, complemented by 2-5% expected organic net sales growth.
公司在亞太地區仍看到良好的市場機會，預計醫療保健需求強勁。
最近的收購預計將爲增長貢獻3-5個百分點，再加上2-5%的有機淨銷售增長。
Risks:
風險：
Quality-related challenges in Acute Care Therapies remain a priority.
Regulatory hurdles with pending CE mark approvals for new ECMO packaging.
急性護理治療方面的質量相關挑戰仍然是重點。
新ECMO包裝的CE標準批准存在監管障礙。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
